United States · Platforms & data · MarketBeat

Royal Bank Of Canada Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Published by MarketBeat · United States 1 h ago

Royal Bank Of Canada dropped their price objective on shares of Eyepoint Pharmaceuticals from $5.00 to $1.00 and set a "sector perform" rating for the company in a research note…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Myriad to sell prenatal health testing business to Labcorp for $210M

MarketWatch

Meet the college students trying to reverse an obscure ban on trading onion futures

The Motley Fool

Royal Bank Of Canada Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Share

Also worth reading

Myriad to sell prenatal health testing business to Labcorp for $210M

Meet the college students trying to reverse an obscure ban on trading onion futures

Dario Amodei's AI Safety Warning Is Colliding With Anthropic's IPO Timeline

Best Tech Stocks Right Now

HSBC CEO warns the AI boom won’t make every data center a good bet

Product DNA and Climate Pacer Launch Solution to Uncover Supply Chain Climate Risks Beyond Tier 1